Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ADVM Adverum Biotechnologies Inc
- Stocks
- Healthcare
- NASDAQ: ADVM
Price (delayed)
$2.06
Market cap
$43.03M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.62
Enterprise value
$66.44M
Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate,
Highlights
ADVM's EPS is up by 45% YoY
Adverum Biotechnologies's equity has shrunk by 51% QoQ but it has increased by 5% YoY
The quick ratio has grown by 13% YoY but it has contracted by 4.9% from the previous quarter
ADVM's gross profit has shrunk by 72% YoY
ADVM's revenue has dropped by 72% year-on-year
Key stats
What are the main financial stats of ADVM
Market
Valuations
Earnings
Shares outstanding
20.89M
Market cap
$43.03M
Enterprise value
$66.44M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.61
Price to sales (P/S)
40.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
66.44
Revenue
$1M
Gross profit
$1M
Operating income
-$139.16M
Net income
-$130.93M
EBIT
-$130.93M
EBITDA
-$105.78M
Free cash flow
-$92.85M
Per share
Balance sheet
Liquidity
EPS
-$6.62
EPS diluted
-$6.62
Free cash flow per share
-$4.69
Book value per share
$3.4
Revenue per share
$0.05
TBVPS
$9.09
Total assets
$179.84M
Total liabilities
$109.13M
Debt
$86.04M
Equity
$70.71M
Working capital
$108.4M
Debt to equity
1.22
Current ratio
5.73
Quick ratio
5.58
Net debt/EBITDA
-0.22
Margins
Efficiency
Dividend
EBITDA margin
-10,577.9%
Gross margin
100%
Net margin
-13,092.7%
Operating margin
-13,915.9%
Return on assets
-56%
Return on equity
-92.7%
Return on invested capital
-77.1%
Return on capital employed
-83.4%
Return on sales
-13,092.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ADVM stock price
How has the Adverum Biotechnologies stock price performed over time
Intraday
-7%
1 week
-31.33%
1 month
-39.94%
1 year
-76.93%
YTD
-55.89%
QTD
-52.86%
Financial performance
How have Adverum Biotechnologies's revenue and profit performed over time
Revenue
$1M
Gross profit
$1M
Operating income
-$139.16M
Net income
-$130.93M
Gross margin
100%
Net margin
-13,092.7%
ADVM's gross profit has shrunk by 72% YoY
ADVM's revenue has dropped by 72% year-on-year
Adverum Biotechnologies's net income has decreased by 32% QoQ and by 7% YoY
Adverum Biotechnologies's net margin has decreased by 32% QoQ
Price vs fundamentals
How does ADVM's price correlate with its fundamentals
Growth
What is Adverum Biotechnologies's growth rate over time
Valuation
What is Adverum Biotechnologies stock price valuation
P/E
N/A
P/B
0.61
P/S
40.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
66.44
ADVM's EPS is up by 45% YoY
The price to book (P/B) is 53% lower than the 5-year quarterly average of 1.3 and 49% lower than the last 4 quarters average of 1.2
Adverum Biotechnologies's equity has shrunk by 51% QoQ but it has increased by 5% YoY
ADVM's revenue has dropped by 72% year-on-year
Efficiency
How efficient is Adverum Biotechnologies business performance
Adverum Biotechnologies's return on equity has decreased by 31% QoQ but it has increased by 13% YoY
ADVM's ROS is down by 31% QoQ
The company's return on assets fell by 29% QoQ
Adverum Biotechnologies's return on invested capital has decreased by 20% QoQ
Dividends
What is ADVM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ADVM.
Financial health
How did Adverum Biotechnologies financials performed over time
The total assets is 65% greater than the total liabilities
The total assets has declined by 23% since the previous quarter but it has increased by 15% year-on-year
Adverum Biotechnologies's total liabilities has increased by 23% YoY and by 21% QoQ
Adverum Biotechnologies's debt is 22% higher than its equity
Adverum Biotechnologies's debt to equity has surged by 184% QoQ and by 20% YoY
Adverum Biotechnologies's equity has shrunk by 51% QoQ but it has increased by 5% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.